This study is recruiting non-metastatic breast cancer survivors who were diagnosed between ages 18 and 51 and are currently 6 months to 5 years post-treatment. Eligible participants must have a score of 5–14 on the PHQ-8 depression screening tool. This study is testing a digital mindfulness meditation-based program. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). Participants will be randomly assigned (like drawing one number out of three at random) to one of three groups: (1) live online mindfulness classes over Zoom, (2) a specially designed mindfulness app, or (3) guided audio meditations. The primary purpose of this study is to determine if different ways of delivering digital mindfulness training can improve mental health and well-being in younger breast cancer survivors. The program is delivered either by live online sessions, through a mobile app, or by listening to guided meditation recordings. Participants can expect to be in this study for about 9 months, including a 6-week training program and questionnaires before, during, and after training. Participants will be enrolled for a duration of 9 months, and a total of 15 patients will be recruited locally over the course of 36 months.

This study is recruiting non-metastatic breast cancer survivors who were diagnosed between ages 18 and 51 and are currently 6 months to 5 years post-treatment. Eligible participants must have a score of 5–14 on the PHQ-8 depression screening tool. This study is testing a digital mindfulness meditation-based program. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). Participants will be randomly assigned (like drawing one number out of three at random) to one of three groups: (1) live online mindfulness classes over Zoom, (2) a specially designed mindfulness app, or (3) guided audio meditations. The primary purpose of this study is to determine if different ways of delivering digital mindfulness training can improve mental health and well-being in younger breast cancer survivors. The program is delivered either by live online sessions, through a mobile app, or by listening to guided meditation recordings. Participants can expect to be in this study for about 9 months, including a 6-week training program and questionnaires before, during, and after training. Participants will be enrolled for a duration of 9 months, and a total of 15 patients will be recruited locally over the course of 36 months.

This study is recruiting non-metastatic breast cancer survivors who were diagnosed between ages 18 and 51 and are currently 6 months to 5 years post-treatment. Eligible participants must have a score of 5–14 on the PHQ-8 depression screening tool. This study is testing a digital mindfulness meditation-based program. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). Participants will be randomly assigned (like drawing one number out of three at random) to one of three groups: (1) live online mindfulness classes over Zoom, (2) a specially designed mindfulness app, or (3) guided audio meditations. The primary purpose of this study is to determine if different ways of delivering digital mindfulness training can improve mental health and well-being in younger breast cancer survivors. The program is delivered either by live online sessions, through a mobile app, or by listening to guided meditation recordings. Participants can expect to be in this study for about 9 months, including a 6-week training program and questionnaires before, during, and after training. Participants will be enrolled for a duration of 9 months, and a total of 15 patients will be recruited locally over the course of 36 months.

This study is recruiting non-metastatic breast cancer survivors who were diagnosed between ages 18 and 51 and are currently 6 months to 5 years post-treatment. Eligible participants must have a score of 5–14 on the PHQ-8 depression screening tool. This study is testing a digital mindfulness meditation-based program. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). Participants will be randomly assigned (like drawing one number out of three at random) to one of three groups: (1) live online mindfulness classes over Zoom, (2) a specially designed mindfulness app, or (3) guided audio meditations. The primary purpose of this study is to determine if different ways of delivering digital mindfulness training can improve mental health and well-being in younger breast cancer survivors. The program is delivered either by live online sessions, through a mobile app, or by listening to guided meditation recordings. Participants can expect to be in this study for about 9 months, including a 6-week training program and questionnaires before, during, and after training. Participants will be enrolled for a duration of 9 months, and a total of 15 patients will be recruited locally over the course of 36 months.

The purpose of this study is to test whether adding cetuximab to standard of care (pembrolizumab) is more effective in shrinking tumor size and increasing survival when compared to being treated with pembrolizumab alone. This study seeks to find if this approach is the same, better, or worse than standard of care for returning or spreading head and neck cancer after previous treatment.

Treatment and follow up for this study may be up to 5 years. The procedures include blood tests, CT or MRI scans, and chemotherapy. Risks include tiredness, anemia, constipation, loss of appetite, joint stiffness, cough, swelling and redness of the skin.

You may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future. Both drugs, pembrolizumab and cetuximab, are already individually approved by the FDA for use in head and neck cancers. However, the benefit of combining the two drugs is being investigated in this study and this study approach is not FDA approved.

There will be about 158 people taking part in this study, approximately 4 subjects will be enrolled at MUSC.

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

Cancer caregivers in emerging and young adulthood (ages 18-35) are an underresearched and unsupported group of caregivers, and yet they are not uncommon. To address this critical support gap, the goal of this study is to develop and pilot test a caregiving support intervention specifically tailored for emerging and young adults caring for a parent with cancer. This phase of the study is intended to capture feedback on the intervention via focus groups with emerging and young adult caregivers of a parent with cancer.